Northern Trust Corp boosted its position in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 939.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 147,483 shares of the company’s stock after purchasing an additional 133,293 shares during the period. Northern Trust Corp owned about 0.75% of Kura Oncology worth $1,372,000 at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. State of Wisconsin Investment Board bought a new position in Kura Oncology during the 2nd quarter valued at about $102,000. Rhumbline Advisers bought a new position in Kura Oncology during the 2nd quarter valued at about $131,000. New York State Common Retirement Fund bought a new position in Kura Oncology during the 2nd quarter valued at about $142,000. Schwab Charles Investment Management Inc. bought a new position in Kura Oncology during the 2nd quarter valued at about $226,000. Finally, Nationwide Fund Advisors lifted its holdings in Kura Oncology by 66.2% during the 2nd quarter. Nationwide Fund Advisors now owns 25,758 shares of the company’s stock valued at $240,000 after purchasing an additional 10,258 shares during the last quarter. 64.26% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts recently issued reports on the stock. Oppenheimer set a $18.00 price target on shares of Kura Oncology and gave the company a “buy” rating in a report on Thursday, November 16th. ValuEngine downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Friday. Zacks Investment Research downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating in a research note on Friday, September 29th. Cann reaffirmed a “buy” rating on shares of Kura Oncology in a research note on Wednesday, November 8th. Finally, Citigroup boosted their target price on shares of Kura Oncology from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $17.60.
Kura Oncology, Inc. (NASDAQ:KURA) opened at $14.95 on Tuesday. Kura Oncology, Inc. has a 12 month low of $4.95 and a 12 month high of $17.50. The company has a debt-to-equity ratio of 0.07, a quick ratio of 13.48 and a current ratio of 13.48.
Kura Oncology (NASDAQ:KURA) last announced its earnings results on Tuesday, November 7th. The company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.01). analysts expect that Kura Oncology, Inc. will post -1.45 EPS for the current fiscal year.
WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/05/northern-trust-corp-has-1-37-million-position-in-kura-oncology-inc-kura.html.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURA).
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.